Brief: Nanoviricides Investigating Possibility Of Using NV-387 For Treatment Of Mpox
26/08/2024 12:39
Aug 26 (Reuters) - NanoViricides Inc NNVC.A :
* NANOVIRICIDES: INVESTIGATING POSSIBILITY OF USING NV-387
FOR
TREATMENT OF MPOX PATIENTS UNDER WHO MEURI PROTOCOL
Source text for Eikon: ID:
Further company coverage: NNVC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments